Drug intelligence / Profile preview

Neomycin + Polymyxin B sulfate + Bacitracin zinc + Hydrocortisone acetate

Development stage
Approved
Lead developer
Fougera Pharmaceuticals
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides
Administration
Ophthalmic
01

Overview

This combination includes antibiotics (neomycin, polymyxin B sulfate, bacitracin zinc) and a corticosteroid (hydrocortisone acetate). It is used to treat steroid-responsive inflammatory ocular conditions where bacterial infection or risk of infection exists. Neomycin and polymyxin B sulfates are active against a wide range of bacteria, including **Staphylococcus aureus**, **Streptococcus pneumoniae**, **Escherichia coli**, **Haemophilus influenzae**, **Klebsiella/Enterobacter** species, **Neisseria** species, and **Pseudomonas aeruginosa**. Bacitracin zinc also contributes to its antimicrobial activity. Hydrocortisone acetate reduces inflammation by suppressing the immune response. - **mechanisms**: The antibiotics work by inhibiting bacterial protein synthesis or disrupting cell membranes, while hydrocortisone acetate reduces inflammation by modulating immune responses.

Brand names
Fougera and Co.
02

Targets

Lipid AC55-PP (Undecaprenyl pyrophosphate)GR (Glucocorticoid receptor)Bacterial Ribosome

Beyond the preview

Go deeper on Neomycin + Polymyxin B sulfate + Bacitracin zinc + Hydrocortisone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neomycin + Polymyxin B sulfate + Bacitracin zinc + Hydrocortisone acetate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call